On Wednesday, February 28, 2024, the Advisory Committee on Immunization Practices’ (ACIP) met and announced the new recommendation for adults ages 65 years and older to receive an additional updated 2023-2024 COVID-19 vaccine dose. With the increased risk of severe disease from COVID-19 in older adults, along with the currently available data on vaccine effectiveness, it is important for adults 65 years and older to follow the recommendation.
Patients should wait at least four months from their last dose, or three months after having COVID-19, before receiving the additional shot. The current shot is the same formulation that was offered in the fall.
Additionally, CDC continues to recommend the 2023–2024 updated COVID-19 vaccine to be given to everyone aged 5 years and older. These individuals should get 1 dose of an updated COVID-19 vaccine to protect against serious illness from COVID-19.
Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of updated COVID-19 vaccine.
Individuals aged 6 months and older, who are moderately or severely immunocompromised may get additional doses of updated COVID-19 vaccine 2 or more months after the last recommended COVID-19 vaccine.
For more information, please visit the CDC website.
|
Are mRNA COVID-19 vaccines from different manufacturers (Moderna and Pfizer BioNTech) interchangeable?
COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:
- Same vaccine not available at the vaccination site at the time of the clinic visit.
- Previous dose unknown.
- Person would otherwise not receive a recommended vaccine dose.
- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication.
The COVID-19 vaccination schedules for people who are not moderately or severely immunocompromised and people who are moderately or severely immunocompromised should be consulted for age-specific information; see also Appendix B for recommended actions following interchangeability-related errors or deviations in administration of COVID-19 vaccines.
For additional information, see Interchangeability of COVID-19 vaccines.
What is the recommendation for children ages 6 months - 4 years who received 2 doses of bivalent mRNA vaccine from different manufacturers (Moderna and Pfizer BioNTech)?
Children ages 6 months–4 years who received the first 2 doses of an mRNA COVID-19 vaccine from different manufacturers should follow a 3-dose schedule. A third dose of either updated (2023–2024 Formula) mRNA vaccine (Moderna or Pfizer-BioNTech) should be administered at least 8 weeks after the second dose.
For additional information, please visit: Interchangeability of COVID-19 vaccines
Interim Clinical Considerations
|
The Maine Immunization Program will no longer require ImmPact users to send in an annual user agreement to renew access. You will still need to send in a new user agreement for new users, role changes, name changes etc.
Please contact the ImmPact Help Desk if you have a user that needs to be terminated. MIP will continue to audit providers to ensure active users are still with practices.
Please contact the ImmPact Help Desk if you have any questions - 207-287-3006 ImmPact.Support@maine.gov
|
MIP is pleased to host an educational lunch and learn on Thursday, March 14, 2024 @ 12:00 PM. During this webinar we will review how to generate several useful reports within ImmPact. Interested in improving your patient population immunization rates? Please join us for this opportunity.
Join Zoom Meeting:
https://mainestate.zoom.us/j/86400912356?pwd=N3d5ekxGQ3kxNVUwdkV4UWc2RGtzUT09
Meeting ID: 864 0091 2356
Passcode: 10817265
The Beyfortus nirsevimab vaccine, recommended for infants, is no longer available to order through ImmPact.
We continue to have a supply of Arexvy for adults 65 years and older who are either under or uninsured through the Adult Vaccine Program.
Ask the experts created a Q&A section focused on RSV vaccines and preventive antibody, includes Q&As based on CDC clinical guidance about adult and infant RSV immunization timing, documentation, and administration. To find the full set of Immunize.org's Ask the Experts RSV Q&As, visit www.immunize.org/ask-experts/topic/rsv/.
Respiratory syncytial virus (RSV) Archives | Immunize.org
Friday, March 4 is International HPV Awareness Day, a great time to spread the word about how the HPV vaccine can reduce the risk of cancers caused by certain strains of this common virus. HPV vaccination should be completed routinely before age 13 years, and as soon as feasible for all unvaccinated teens and young adults through age 26. Adults age 27 through 45 who want protection may be vaccinated after a discussion with their healthcare provider.
Vaccination prevents almost 90% of cervical cancer cases. Both men and women are at risk for HPV-related cancers so it's important to receive the HPV vaccine series according to the recommended vaccination schedules.
|
